134 related articles for article (PubMed ID: 16458132)
1. Upstream/downstream glycoprotein IIb/IIIa in non-ST-segment elevation myocardial infarction.
Ben-Yehuda O
J Am Coll Cardiol; 2006 Feb; 47(3):538-40. PubMed ID: 16458132
[No Abstract] [Full Text] [Related]
2. GP IIb/IIIa inhibitors: an evidence-based approach to their use.
Med Manag Netw; 1999 Mar; 7(3):5-9. PubMed ID: 10346546
[No Abstract] [Full Text] [Related]
3. Platelet glycoprotein IIb/IIIa inhibition as adjunctive therapy during primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction.
Young JJ
J Invasive Cardiol; 2005 Jun; 17(6):300-1. PubMed ID: 16003003
[No Abstract] [Full Text] [Related]
4. Cost-effectiveness of upstream versus selective glycoprotein IIb/IIIa inhibitors for acute coronary syndromes.
Boersma E
J Am Coll Cardiol; 2007 Jan; 49(2):276; author reply 277. PubMed ID: 17222743
[No Abstract] [Full Text] [Related]
5. Cost and effectiveness of glycoprotein IIb/IIIa-receptor inhibitors in patients with acute myocardial infarction undergoing percutaneous coronary intervention.
McCollam PL; Foster DA; Riesmeyer JS
Am J Health Syst Pharm; 2003 Jun; 60(12):1251-6. PubMed ID: 12845921
[TBL] [Abstract][Full Text] [Related]
6. The benefits of platelet glycoprotein IIb/IIIa receptor inhibition during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: drug-specific or class effect?
Brener SJ
J Am Coll Cardiol; 2009 May; 53(18):1674-6. PubMed ID: 19406343
[No Abstract] [Full Text] [Related]
7. The role of risk stratification in the decision to provide upstream versus selective glycoprotein IIb/IIIa inhibitors for acute coronary syndromes: a cost-effectiveness analysis.
Glaser R; Glick HA; Herrmann HC; Kimmel SE
J Am Coll Cardiol; 2006 Feb; 47(3):529-37. PubMed ID: 16458131
[TBL] [Abstract][Full Text] [Related]
8. Selection of glycoprotein IIb/IIIa inhibitors for upstream use in patients with diabetes experiencing unstable angina or non-ST segment elevation myocardial infarction. What have we learned in the last 10 years?
Silva MA; Gandhi PJ
J Clin Pharm Ther; 2004 Dec; 29(6):497-510. PubMed ID: 15584937
[TBL] [Abstract][Full Text] [Related]
9. Cost efficacy of platelet glycoprotein IIb/IIIa antagonists in clinical trials and clinical practice.
Young JJ; Kereiakes DJ
J Interv Cardiol; 2002 Apr; 15(2):115-20. PubMed ID: 12063806
[No Abstract] [Full Text] [Related]
10. [Inhibitors of platelet glycoprotein IIb-IIIa in cardiology].
Obradović S; Gligić B; Djordjević D; Jovicić A; Romanović R; Ratković N; Dincić D; Orozović V; Nikolić G
Vojnosanit Pregl; 2001; 58(1):65-72. PubMed ID: 11419288
[No Abstract] [Full Text] [Related]
11. The glycoprotein IIb/IIIa receptor inhibitor (abciximab) in ST-segment elevation myocardial infarction.
Mesquita A; Baptista J; Palos J; Seabra-Gomes R
J Invasive Cardiol; 1999 Jun; 11(6):379-82. PubMed ID: 10745556
[TBL] [Abstract][Full Text] [Related]
12. Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE).
Tricoci P; Peterson ED; Chen AY; Newby LK; Harrington RA; Greenbaum AB; Cannon CP; Gibson CM; Hoekstra JW; Pollack CV; Ohman EM; Gibler WB; Roe MT
Am J Cardiol; 2007 May; 99(10):1389-93. PubMed ID: 17493466
[TBL] [Abstract][Full Text] [Related]
13. Bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in drug-eluting stent implantations in the absence of acute myocardial infarction: clinical and economic results.
Mishkel GJ; Moore AL; Markwell SJ; Ligon RW
J Invasive Cardiol; 2007 Feb; 19(2):63-8. PubMed ID: 17268039
[TBL] [Abstract][Full Text] [Related]
14. Are stenting and glycoprotein IIb/IIIa blockade of good value in primary percutaneous coronary intervention?
Cole JH; Weintraub WS
Circulation; 2003 Dec; 108(23):2831-3. PubMed ID: 14662689
[No Abstract] [Full Text] [Related]
15. [Antithrombotic treatment of acute coronary syndromes without ST-segment elevation].
Radke PW; Schunkert H
Dtsch Med Wochenschr; 2006 Nov; 131(47 Suppl 7):S204-7. PubMed ID: 17109249
[No Abstract] [Full Text] [Related]
16. Increased reperfusion by glycoprotein IIb/IIIa receptor antagonist administration in case of unsuccessful and failed thrombolysis in patients with acute myocardial infarction: a pilot study.
Di Pasquale P; Sarullo FM; Cannizzaro S; Vitrano MG; Giubilato A; Scalzo S; Giambanco F; Paterna S
Ital Heart J; 2001 Oct; 2(10):751-6. PubMed ID: 11721719
[TBL] [Abstract][Full Text] [Related]
17. Incorporating platelet glycoprotein IIb/IIIa inhibition in critical pathways: unstable angina/non-ST-segment elevation myocardial infarction.
Cannon CP
Clin Cardiol; 1999 Aug; 22(8 Suppl):IV30-6. PubMed ID: 10492851
[TBL] [Abstract][Full Text] [Related]
18. Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials).
Rebeiz AG; Johanson P; Green CL; Crater SW; Roe MT; Langer A; Giugliano RP; Lincoff AM; Newby LK; Harrington RA; Topol EJ; Califf RM; Wagner GS; Krucoff MW
Am J Cardiol; 2005 Mar; 95(5):611-4. PubMed ID: 15721101
[TBL] [Abstract][Full Text] [Related]
19. The impact of GP IIb/IIIa inhibitors during primary percutaneous coronary intervention in acute myocardial infarction patients.
Lavi S; Gruberg L; Kapeliovich M; Hammerman H; Boulos M; Grenadier E; Aronson D; Markiewicz W; Beyar R
J Invasive Cardiol; 2005 Jun; 17(6):296-9. PubMed ID: 16003002
[TBL] [Abstract][Full Text] [Related]
20. Platelet glycoprotein IIb/IIIa receptor blockade after coronary angioplasty.
Khan SS; Forrester J
N Engl J Med; 1997 Oct; 337(17):1243; author reply 1244-5. PubMed ID: 9340527
[No Abstract] [Full Text] [Related]
[Next] [New Search]
